HANAUER, S. Delayed-Release Oral Mesalamine at 4.8 g/day (800mg tablet) for the Treatment of Moderately Active Ulcerative Colitis : The ASCEND II Trial. Am J Gastroenterol. 2005, 100, 2478-2485
SANDBORN, WJ. MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis : a combined analysis of two randomized, double-blind, placebo-controlled trials. Aliment Pharmacol Ther. 2007, 26, 205-215
KANE, S. Medication nonadherence and outcomes of patients with quiescent ulcerative colitis. Am J Med. 2003, 114, 39-43